Crispr Therapeut Stock Price, News & Analysis

CRISPR Therapeutics (NASDAQ: CRSP) has reported positive additional Phase 1 data for its cardiovascular drug candidate CTX310, targeting ANGPTL3. The trial demonstrated impressive dose-dependent reductions of up to 82% in triglycerides and 86% in LDL, with a well-tolerated safety profile.

The company plans to present complete Phase 1 data for CTX310 in H2 2025. Additionally, CRISPR provided updates on two other cardiovascular programs: CTX320 targeting LPA gene, with data now expected in H1 2026, and CTX340 for refractory hypertension, which is advancing toward IND/CTA filings.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in two major investor conferences in June 2025. The company's senior management will present at William Blair's 45th Annual Growth Stock Conference on June 3 at 11:20 a.m. CT and at the Goldman Sachs' 46th Annual Global Healthcare Conference on June 9 at 3:20 p.m. ET. Live webcasts will be available on the company's website, with replays accessible for 14 days after the presentations.

CRISPR Therapeutics and Sirius Therapeutics have announced a strategic partnership to develop siRNA therapies, with a primary focus on SRSD107, a Factor XI siRNA therapy for thromboembolic disorders. The collaboration involves a $95 million upfront payment from CRISPR ($25M cash + $70M equity). Phase 1 trials of SRSD107 showed promising results with >93% reduction in FXI activity and sustained efficacy up to 6 months post-dosing. The partnership includes a 50-50 cost and profit-sharing structure for SRSD107, with CRISPR leading U.S. commercialization and Sirius handling Greater China. Additionally, CRISPR gains rights to license two more siRNA programs. SRSD107 targets various conditions including atrial fibrillation, VTE, and cancer-associated thrombosis, offering potential advantages like lower bleeding risk and infrequent dosing. A Phase 2 trial is being initiated for VTE prevention in knee arthroplasty patients.

CRISPR Therapeutics (NASDAQ: CRSP) reported positive Q1 2025 results and breakthrough data from CTX310™'s Phase 1 trial. The trial demonstrated significant reductions in triglycerides (up to 82%) and LDL (up to 81%) with a well-tolerated safety profile. The company's flagship product CASGEVY® continues to expand globally with over 65 authorized treatment centers and 90+ patients having cells collected. Financial highlights include a strong cash position of $1.86 billion, though the company reported a net loss of $136.0 million. R&D expenses decreased to $72.5 million from $76.2 million YoY. The company's pipeline shows progress with ongoing trials for CTX320™, CTX112™, and CTX131™, with updates expected throughout 2025. CASGEVY® has secured reimbursement agreements in multiple regions and expects commercial production in Portsmouth, NH in H2 2025.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's senior management team will conduct a fireside chat on Tuesday, April 8, 2025, at 12:45 p.m. ET.

The presentation will be accessible through a live webcast on the company's investor relations website under the 'Events & Presentations' section. Interested parties can access the replay of the webcast, which will remain available for 14 days after the presentation.

CRISPR Therapeutics (Nasdaq: CRSP) announced that Chief Operating Officer Julianne Bruno will step down from her position effective April 11, 2025, to pursue external opportunities. Bruno has served the company for six years, during which her leadership was important in advancing the company's hematology and oncology programs. CEO Samarth Kulkarni acknowledged her contributions in maturing the company's operating model and various cross-functional initiatives.

CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company specializing in gene-based medicines, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's senior management team will deliver a presentation on March 3, 2025, at 10:30 a.m. ET.

Investors and interested parties can access a live webcast of the fireside chat through the company's website under the 'Events & Presentations' section. The presentation recording will remain available for replay on the company's website for 14 days following the event.

CRISPR Therapeutics reports Q4 and full year 2024 results, highlighting significant progress across its portfolio. The company's CASGEVY® treatment continues to gain momentum with more than 50 authorized treatment centers activated globally and over 50 patients having cells collected across all regions by end of 2024.

The company maintains a strong financial position with $1.9 billion in cash and equivalents as of December 31, 2024. Q4 2024 financial results show R&D expenses of $82.2 million (down from $95.1 million in Q4 2023) and G&A expenses of $18.1 million. The company reported a net loss of $37.3 million for Q4 2024, compared to net income of $89.3 million in Q4 2023.

Key developments include ongoing clinical trials for next-generation CAR T products CTX112™ and CTX131™, and in vivo gene editing candidates CTX310™ and CTX320™. The company also established a strategic partnership with Nkure Therapeutics for CTX112 development in India.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company specializing in gene-based medicines for serious diseases, has announced its participation in the upcoming Guggenheim SMID Cap Biotech Conference. The company's senior management team will deliver a presentation on Wednesday, February 5, 2025, at 2:00 p.m. ET.

The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section. Interested parties can view the fireside chat through the investor relations portal at https://crisprtx.gcs-web.com/events. The recording will remain available for replay on the company's website for 14 days after the presentation.